Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01750827 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of SB 659032 on Platelet Function
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01750827 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 14 participants.
The verdict
NCT01750827, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This will be an open-label, single dose, single period study. Approximately 14 subjects will receive one dose of 250 mg of non-enteric coated SB-659032 following a low-fat breakfast. This study will evaluate whether SB-659032 has an effect on platelet function as determined by platelet aggregation tests using the agonists ADP and collagen. Blood samples for PK analysis and measurement of Lp-PLA2 activity will also be collected
Interventions
- DRUG SB659032
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2004-09 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01750827
The ClinicalTrials.gov registry entry for NCT01750827 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB659032 is the first listed.
NCT01750827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01750827 about?
NCT01750827 is a clinical study titled "A Study to Assess the Effect of SB 659032 on Platelet Function". This will be an open-label, single dose, single period study. Approximately 14 subjects will receive one dose of 250 mg of non-enteric coated SB-659032 following a low-fat breakfast. This study will evaluate whether SB-659032 has an effect on platelet function as determined by platelet aggregation t...
What is the current status of trial NCT01750827?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2004-09. Estimated completion is 2004-11.
What interventions are being tested in trial NCT01750827?
The interventions under investigation include: SB659032 (DRUG).
Who is sponsoring clinical trial NCT01750827?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.